This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Selker and colleagues, Dr Opie, and Drs Arora and Katragadda suggest that GIK infusion in acute MI is more likely to be beneficial when given before reperfusion therapy but that in our present study GIK was used primarily after reperfusion. However, we found no benefit of GIK therapy in any subgroup of interest (all of which were sizable given our total population of 22 943 patients), including those who underwent reperfusion therapy (n = 18 735), received primary PCI (n = 2626), underwent reperfusion after randomization (n = 10 041) so that GIK was administered before or concurrently with reperfusion therapy, or were enrolled in ECLA centers (n = 3798) (Figure).

Figure appears in full text version. Figure. Death at 30 Days by Subgroup The size of the data markers indicates the relative sample size of the number of patients in the denominators for each of the analyses. Error bars indicate 95% confidence intervals (CIs). CREATE indicates Clinical Trial of Reviparin and . . . [Full Text of this Article]

Abhinav Goyal, MD, MHS
agoyal@cardio.on.ca
Population Health Research Institute
Hamilton, Ontario, Canada

Rafael Díaz, MD
Estudios Cardiologicos Latinoamerica
Rosario, Argentina

Shamir R. Mehta, MD, MSc
McMaster University
Hamilton

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial
The CREATE-ECLA Trial Group Investigators*
JAMA. 2005;293(4):437-446.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Harry P. Selker, Joanne Ingwall, and Charles E. Rackley
JAMA. 2008;299(20):2385.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Lionel H. Opie
JAMA. 2008;299(20):2385-2386.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Rohit R. Arora and Srikanth Katragadda
JAMA. 2008;299(20):2386.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Ajay Chaudhuri, Richard Nesto, and Paresh Dandona
JAMA. 2008;299(20):2386-2387.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute Myocardial Infarction, Hyperglycemia, and Insulin
Dandona et al.
J Am Coll Cardiol 2009;53:1437-1439.
FULL TEXT  

CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome
Cosentino et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points
Goyal et al.
Diabetes and Vascular Disease Research 2008;5:276-284.
ABSTRACT